![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 25, 2022 8:05:42 AM
1) company states and it is actually required if one wants to file in a jurisdiction, that the SAP would be shopped by all 4 RAs and approved before datalock. Time between the anoincement that they are ready to proceed towards loch (11/2018) to lock (10/5/2020) suggests negotiations were required.
2) data lock happened on 10/5/2020
3) shortly after the RAs from UK and EMA post new study design and endpoints on their clinical trial sites indicating they have approved new design
4) US does not because it is the company’s responsibility to update clinical trials site, but they don’t and shorts bash saying they didn’t get US buy in. A few months back, however, Dr. LindaLiau confirms it was submitted and not rejected by FDA. This is how they do things until actual drug approval. Even an SPA is non-binding. So, since companies can’t speak for FDA and not rejecting is not quite the same as approving, NWBO doesn’t update the site.
5) LL presents database and study design with new SAP at Mt. Sinai in May 19, 2021. This demonstrates the company has alll elements to submit the BLA (did they? … 12 months tick tock)
6) late August 2021 company begins a premarket promotion campaign at ABTA, continues with hardly undbranded advertisement in October magazine, and then has the infamous Tote bag at SNO in November. Booths are pulled from these meetings. (Did this start the accelerated BLA acceptance, add 6 months and one 3 months no cause extension and you get end of May, but I like the first option better as it adds more flexibility to timeline plus or minus 2 months, although FDA can issue another extension to buy more time if needed)
7) NYAS presents TLD, but no PR…why is that? Is it part of a short trap as promised with accompanying FBi sting operation? Sure suspicious that great data drops shareprice 70%. On 70+ million shares traded.
8) they speak for the FDA and post new design & first 2 endpoints on clinical trials.gov. What changed? Why are they now comfortable speaking for FDA? Also, price does not climb despite this confirmation & whacking of primary short thesis. (I believe this is proof that FDA returned the “red-lined label after up to 30 days” following NWBO submission of final step “draft label” if they are will to accept FDA changes with minor language tweeks…the deal is done.
9) No PR… see also 7
10) clintrials only has 2 endpoints, why? Well, this is different than EU because the non-binding agreement with FDA previously, switched to binding after the data was agreed upon (and now presented). The third endpoint missed (curious they ordered the least likely endpoint 3rd… probably an FDA requirement to give FDA more flexibility about 4, 5, and 6.
11) This proves that the endpoints were ordered to preserve alpha and keep hurdle at p=0.05. After the analysis now 4, 5, and 6 are post hos but not necessarily excluded from the label. Dealers choice not companies. This also indirectly proves #10.
12) Is this an FBI sting operation? How to catch criminals?
13) APPROVALS are PENDING … who is on first? What is on second? Does is third really mean all four at once? No PR YET!!!
14) ASCO product theater is on opening day of the industry/scientific congress and NWBO gets access to the media room. What is going to be said.
15) Enquiring minds want to know about BLA submissions. I already know
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM